Tonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | 2026-04-02 18:43:23 | 14.02 | 0.12 | 0.83 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNXP | 0001430306 | Tonix Pharmaceuticals Holding Corp. | US8902608392 | 529900ACPKP9QW20GX48 | 261434750 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | NV | 200 CONNELL DRIVE, SUITE 3100 | BERKELEY HEIGHTS | NJ | 07922 | UNITED STATES | US | 212-980-9155 | 200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NJ, 07922 | 200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NJ, 07922 | TAMANDARE EXPLORATIONS INC. | Biotechnology | — | — | — | http://www.tonixpharma.com | 271,370,839 | 12,788,069 | 13,405,401 | Tonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. | 2026-04-02 18:52:56 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 271,370,839 | 264,513,713 | 3,857.5011 | 13,405,401 | 6,970,520 | 108.324 |
| 2024 | 6,857,126 | -10,139,157 | -59.6551 | 6,434,881 | -78,055,981 | -92.3839 |
| 2023 | 16,996,283 | -33,025,871 | -66.0225 | 84,490,862 | 21,951,365 | 35.1 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Bradley Saenger | Chief Financial Officer | 2025 | 502,944 | 251,450 | 0 | 0 | 0 | 1,143,513 |
| Gregory Sullivan | Chief Medical Officer | 2025 | 519,168 | 259,600 | 0 | 0 | 0 | 1,216,542 |
| Seth Lederman | Chief Executive Officer | 2025 | 702,000 | 596,700 | 0 | 0 | 0 | 3,168,830 |
| Jessica Morris | Chief Operations Officer | 2025 | 522,912 | 261,450 | 0 | 0 | 0 | 1,226,269 |
| Jessica Morris | Chief Operations Officer | 2024 | 494,000 | 180,310 | 0 | 0 | 0 | 887,741 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 142 |
| 2024 | 81 |
| 2023 | 103 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 13,107,000 | 10,094,000 | 7,768,000 |
| Cost Of Revenue | 6,640,000 | 7,765,000 | 4,741,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 44,486,000 | 39,972,000 | 86,655,000 |
| General And Administrative Expenses | 87,684,000 | 40,101,000 | 34,752,000 |
| Operating Expenses | 138,810,000 | 146,795,000 | 126,148,000 |
| Operating Income | -125,703,000 | -136,701,000 | -118,380,000 |
| Net Income | -124,021,000 | -130,036,000 | -116,658,000 |
| Earnings Per Share Basic | -14.57 | -176.6 | -6.85 |
| Earnings Per Share Diluted | -14.57 | -176.6 | -6.85 |
| Weighted Average Shares Outstanding Basic | 8,511,318 | 736,339 | 17,039,309 |
| Weighted Average Shares Outstanding Diluted | 8,511,318 | 736,339 | 17,039,309 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 207,637,000 | 98,776,000 | 24,948,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 6,271,000 | 3,683,000 | 4,590,000 |
| Inventories | — | 8,408,000 | 13,639,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 228,876,000 | 119,002,000 | 47,768,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 44,456,000 | 42,252,000 | 94,028,000 |
| Other Assets Non Current | 2,175,000 | 951,000 | 1,129,000 |
| Total Assets Non Current | 48,295,000 | 43,888,000 | 106,689,000 |
| Total Assets | 277,171,000 | 162,890,000 | 154,457,000 |
| Accounts Payable | 8,114,000 | 4,546,000 | 3,782,000 |
| Deferred Revenue | 3,425,000 | 1,816,000 | 2,980,000 |
| Short Term Debt | — | 2,820,000 | 2,350,000 |
| Other Liabilities Current | — | — | 44,000 |
| Total Liabilities Current | 30,837,000 | 18,307,000 | 18,884,000 |
| Long Term Debt | — | 8,650,000 | 11,000,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 1,184,000 | 5,025,000 | 30,048,000 |
| Total Liabilities | 32,021,000 | 23,332,000 | 48,932,000 |
| Common Stock | 13,000 | 4,000 | 59,000 |
| Retained Earnings | -854,715,000 | -730,694,000 | -600,658,000 |
| Accumulated Other Comprehensive Income | -289,000 | -255,000 | -232,000 |
| Total Shareholders Equity | 245,150,000 | 139,558,000 | 105,525,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,900,000 | 2,900,000 | 3,800,000 |
| Share Based Compensation Expense | 6,017,000 | 4,778,000 | 9,275,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 2,619,000 | 3,683,000 | — |
| Change In Inventories | -1,726,000 | -3,741,000 | -61,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,994,000 | 927,000 | -3,490,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -99,844,000 | -60,925,000 | -102,003,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 3,369,000 | 120,000 | 7,895,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -4,528,000 | -120,000 | -29,070,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 237,940,000 | 140,195,000 | 18,939,000 |
| Repurchase Of Common Stock | 13,760,000 | — | 13,965,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 9,650,000 | 2,350,000 | — |
| Other Financing Activities | — | 27,000 | 29,000 |
| Cash From Financing Activities | 214,530,000 | 134,872,000 | 36,517,000 |
| Change In Cash | 110,127,000 | 73,831,000 | -94,621,000 |
| Cash At End Of Period | 207,637,000 | 98,776,000 | 24,948,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 89,000 | 1,234,000 | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -14.57 | -176.6 | -6.85 |
| Price To Earnings Ratio | -1.0721 | -0.1867 | -188.2628 |
| Earnings Growth Rate | -91.7497 | 2,478.1022 | 109.4801 |
| Price Earnings To Growth Ratio | 0.0117 | -0.0001 | -1.7196 |
| Book Value Per Share | 28.8028 | 189.5296 | 6.193 |
| Price To Book Ratio | 0.5423 | 0.174 | 208.234 |
| Ebitda | -122,032,000 | -127,136,000 | -112,858,000 |
| Enterprise Value | — | -63,021,539.78 | 21,962,294,886.4 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | 0.0822 | 0.1265 |
| Capital Expenditures | 4,104,000 | -48,876,000 | 4,014,000 |
| Free Cash Flow | -103,948,000 | -12,049,000 | -106,017,000 |
| Return On Equity | -0.5059 | -0.9318 | -1.1055 |
| One Year Beta | 0.9988 | 1.3337 | 1.3563 |
| Three Year Beta | 1.1511 | 1.2888 | 1.3391 |
| Five Year Beta | 1.2481 | 0.5888 | 0.5979 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| LEDERMAN SETH | Director, Chief Executive Officer | 2026-03-31 | 5,000 | A | 20,001 |
| LEDERMAN SETH | Director, Chief Executive Officer | 2026-03-18 | 15,000 | A | 15,001 |
| LEDERMAN SETH | Director, Chief Executive Officer | 2026-02-24 | 134,504 | A | 134,504 |
| LEDERMAN SETH | Director, Chief Executive Officer | 2026-02-24 | 134,503 | A | 134,503 |
| Fogarty Siobhan | Chief Technology Officer | 2026-02-24 | 39,012 | A | 39,012 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 418,741 | 26,808 | 15.62 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 625 | 40 | 15.625 |
| Sunbelt Securities, Inc. | 2025-12-31 | 78 | 5 | 15.6 |
| Caitlin John, LLC | 2025-12-31 | 1,203 | 77 | 15.6234 |
| AQR CAPITAL MANAGEMENT LLC | 2025-12-31 | 312,713 | 20,020 | 15.62 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 5,240 | 90,337.6 | 0.0065 |
| ProFunds | 2026-01-31 | SMALL-CAP PROFUND SERVICE CLASS | SLPSX | 13 | 224.12 | 0.003 |
| ProFunds | 2026-01-31 | SMALL-CAP PROFUND INVESTOR CLASS | SLPIX | 13 | 224.12 | 0.003 |
| ProFunds | 2026-01-31 | ULTRASMALL-CAP PROFUND SERVICE CLASS | UAPSX | 148 | 2,551.52 | 0.0048 |
| ProFunds | 2026-01-31 | ULTRASMALL-CAP PROFUND INVESTOR CLASS | UAPIX | 148 | 2,551.52 | 0.0048 |